CA2369172A1 - Ste20-related protein kinases - Google Patents
Ste20-related protein kinases Download PDFInfo
- Publication number
- CA2369172A1 CA2369172A1 CA002369172A CA2369172A CA2369172A1 CA 2369172 A1 CA2369172 A1 CA 2369172A1 CA 002369172 A CA002369172 A CA 002369172A CA 2369172 A CA2369172 A CA 2369172A CA 2369172 A1 CA2369172 A1 CA 2369172A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- amino acid
- set forth
- kinase
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108060006633 protein kinase Proteins 0.000 title description 54
- 102000001253 Protein Kinase Human genes 0.000 title description 53
- 108091000080 Phosphotransferase Proteins 0.000 claims abstract description 486
- 102000020233 phosphotransferase Human genes 0.000 claims abstract description 480
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 333
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 332
- 229920001184 polypeptide Polymers 0.000 claims abstract description 330
- 238000000034 method Methods 0.000 claims abstract description 195
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 186
- 201000010099 disease Diseases 0.000 claims abstract description 103
- 102100026287 Misshapen-like kinase 1 Human genes 0.000 claims abstract description 72
- 101000987297 Homo sapiens Serine/threonine-protein kinase PAK 4 Proteins 0.000 claims abstract description 45
- 101000987295 Homo sapiens Serine/threonine-protein kinase PAK 5 Proteins 0.000 claims abstract description 36
- 101000983111 Homo sapiens Serine/threonine-protein kinase PAK 6 Proteins 0.000 claims abstract description 31
- 102100027940 Serine/threonine-protein kinase PAK 4 Human genes 0.000 claims abstract description 28
- 238000011282 treatment Methods 0.000 claims abstract description 20
- 102100026840 Serine/threonine-protein kinase PAK 6 Human genes 0.000 claims abstract description 17
- 150000001413 amino acids Chemical class 0.000 claims description 421
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 351
- 241000282414 Homo sapiens Species 0.000 claims description 289
- 150000007523 nucleic acids Chemical class 0.000 claims description 224
- 102000039446 nucleic acids Human genes 0.000 claims description 204
- 108020004707 nucleic acids Proteins 0.000 claims description 204
- 230000000694 effects Effects 0.000 claims description 190
- 210000004027 cell Anatomy 0.000 claims description 158
- 239000002773 nucleotide Substances 0.000 claims description 117
- 125000003729 nucleotide group Chemical group 0.000 claims description 116
- 239000000523 sample Substances 0.000 claims description 111
- 239000000126 substance Substances 0.000 claims description 95
- 101000573441 Homo sapiens Misshapen-like kinase 1 Proteins 0.000 claims description 85
- 208000035475 disorder Diseases 0.000 claims description 83
- 239000012634 fragment Substances 0.000 claims description 73
- 230000000295 complement effect Effects 0.000 claims description 65
- 230000027455 binding Effects 0.000 claims description 46
- 238000009396 hybridization Methods 0.000 claims description 44
- 241000124008 Mammalia Species 0.000 claims description 41
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 41
- 238000001514 detection method Methods 0.000 claims description 41
- 239000002853 nucleic acid probe Substances 0.000 claims description 41
- 208000037765 diseases and disorders Diseases 0.000 claims description 38
- 206010028980 Neoplasm Diseases 0.000 claims description 37
- 210000000056 organ Anatomy 0.000 claims description 36
- 238000002054 transplantation Methods 0.000 claims description 36
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 35
- 239000013598 vector Substances 0.000 claims description 35
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 34
- 208000006011 Stroke Diseases 0.000 claims description 34
- 201000011510 cancer Diseases 0.000 claims description 34
- 201000006370 kidney failure Diseases 0.000 claims description 34
- 230000036542 oxidative stress Effects 0.000 claims description 34
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 33
- 208000010125 myocardial infarction Diseases 0.000 claims description 33
- 230000009870 specific binding Effects 0.000 claims description 28
- 238000012360 testing method Methods 0.000 claims description 27
- 230000003993 interaction Effects 0.000 claims description 23
- 238000005406 washing Methods 0.000 claims description 22
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 claims description 20
- 238000013518 transcription Methods 0.000 claims description 20
- 230000035897 transcription Effects 0.000 claims description 20
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 16
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 16
- 230000008859 change Effects 0.000 claims description 12
- 210000004408 hybridoma Anatomy 0.000 claims description 12
- 241000972773 Aulopiformes Species 0.000 claims description 11
- 238000012544 monitoring process Methods 0.000 claims description 11
- 235000019515 salmon Nutrition 0.000 claims description 11
- 238000000338 in vitro Methods 0.000 claims 10
- 229940043355 kinase inhibitor Drugs 0.000 claims 10
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 10
- 229910000162 sodium phosphate Inorganic materials 0.000 claims 10
- 235000019799 monosodium phosphate Nutrition 0.000 claims 9
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims 9
- 101000613565 Homo sapiens PRKC apoptosis WT1 regulator protein Proteins 0.000 claims 1
- 101001113471 Homo sapiens Proteinase-activated receptor 4 Proteins 0.000 claims 1
- 102100023710 Proteinase-activated receptor 4 Human genes 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract description 41
- 238000003745 diagnosis Methods 0.000 abstract description 2
- 235000001014 amino acid Nutrition 0.000 description 301
- 229940024606 amino acid Drugs 0.000 description 301
- 108090000623 proteins and genes Proteins 0.000 description 115
- 102000004169 proteins and genes Human genes 0.000 description 80
- 235000018102 proteins Nutrition 0.000 description 79
- 210000004899 c-terminal region Anatomy 0.000 description 72
- 239000002299 complementary DNA Substances 0.000 description 57
- 241001529936 Murinae Species 0.000 description 56
- 230000003197 catalytic effect Effects 0.000 description 56
- 230000000875 corresponding effect Effects 0.000 description 35
- 230000036961 partial effect Effects 0.000 description 32
- 102100026764 Serine/threonine-protein kinase 24 Human genes 0.000 description 31
- 101000628647 Homo sapiens Serine/threonine-protein kinase 24 Proteins 0.000 description 30
- 230000001105 regulatory effect Effects 0.000 description 30
- 230000006870 function Effects 0.000 description 29
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 28
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 27
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 26
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 26
- 125000000539 amino acid group Chemical group 0.000 description 25
- 230000000977 initiatory effect Effects 0.000 description 24
- 230000014509 gene expression Effects 0.000 description 23
- 125000006850 spacer group Chemical group 0.000 description 23
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 22
- 101100311456 Caenorhabditis elegans kin-18 gene Proteins 0.000 description 22
- 101100401589 Caenorhabditis elegans mig-15 gene Proteins 0.000 description 22
- 108020004414 DNA Proteins 0.000 description 22
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 22
- 229930182817 methionine Natural products 0.000 description 22
- 238000004458 analytical method Methods 0.000 description 19
- 108020005345 3' Untranslated Regions Proteins 0.000 description 17
- 108700026244 Open Reading Frames Proteins 0.000 description 17
- 102100028194 Mitogen-activated protein kinase kinase kinase kinase 4 Human genes 0.000 description 16
- 230000003834 intracellular effect Effects 0.000 description 16
- 101710144518 Mitogen-activated protein kinase kinase kinase kinase 4 Proteins 0.000 description 15
- 230000002159 abnormal effect Effects 0.000 description 15
- 230000026731 phosphorylation Effects 0.000 description 15
- 238000006366 phosphorylation reaction Methods 0.000 description 15
- 108010076504 Protein Sorting Signals Proteins 0.000 description 14
- 102100030571 STE20-like serine/threonine-protein kinase Human genes 0.000 description 14
- YGZWVPBHYABGLT-KJEVXHAQSA-N Thr-Pro-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 YGZWVPBHYABGLT-KJEVXHAQSA-N 0.000 description 14
- 230000004913 activation Effects 0.000 description 14
- 150000001875 compounds Chemical class 0.000 description 14
- 230000019491 signal transduction Effects 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 14
- 102100028192 Mitogen-activated protein kinase kinase kinase kinase 2 Human genes 0.000 description 13
- 101710157230 STE20-like serine/threonine-protein kinase Proteins 0.000 description 13
- 101710183953 Serine/threonine-protein kinase 25 Proteins 0.000 description 13
- 101710144533 Mitogen-activated protein kinase kinase kinase kinase 2 Proteins 0.000 description 12
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 12
- 102100026737 Serine/threonine-protein kinase 25 Human genes 0.000 description 12
- 230000008488 polyadenylation Effects 0.000 description 12
- 230000002103 transcriptional effect Effects 0.000 description 12
- 102100027609 Rho-related GTP-binding protein RhoD Human genes 0.000 description 11
- 238000004422 calculation algorithm Methods 0.000 description 11
- 101800001318 Capsid protein VP4 Proteins 0.000 description 10
- 108091026890 Coding region Proteins 0.000 description 10
- 230000001413 cellular effect Effects 0.000 description 10
- -1 tyrosine amino acids Chemical class 0.000 description 10
- 108020003589 5' Untranslated Regions Proteins 0.000 description 9
- 101000701497 Homo sapiens STE20/SPS1-related proline-alanine-rich protein kinase Proteins 0.000 description 9
- 101150073911 STK gene Proteins 0.000 description 9
- 239000000284 extract Substances 0.000 description 9
- 238000002887 multiple sequence alignment Methods 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- 108020004705 Codon Proteins 0.000 description 8
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 8
- 101000628693 Homo sapiens Serine/threonine-protein kinase 25 Proteins 0.000 description 8
- 102000042887 STE20 family Human genes 0.000 description 8
- 108091082301 STE20 family Proteins 0.000 description 8
- 102100030491 STE20/SPS1-related proline-alanine-rich protein kinase Human genes 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 230000037361 pathway Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 238000003752 polymerase chain reaction Methods 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 6
- 102000000395 SH3 domains Human genes 0.000 description 6
- 108050008861 SH3 domains Proteins 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 238000010367 cloning Methods 0.000 description 6
- 238000012217 deletion Methods 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 235000008521 threonine Nutrition 0.000 description 6
- 102100037912 Cyclin-dependent kinase 11A Human genes 0.000 description 5
- 101000738403 Homo sapiens Cyclin-dependent kinase 11A Proteins 0.000 description 5
- 101001066435 Homo sapiens Hepatocyte growth factor-like protein Proteins 0.000 description 5
- 101000880431 Homo sapiens Serine/threonine-protein kinase 4 Proteins 0.000 description 5
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 5
- 102100037629 Serine/threonine-protein kinase 4 Human genes 0.000 description 5
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 5
- 239000004473 Threonine Substances 0.000 description 5
- 239000012082 adaptor molecule Substances 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 210000001072 colon Anatomy 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 238000006471 dimerization reaction Methods 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 102000050788 human PAK4 Human genes 0.000 description 5
- 102000054042 human PAK5 Human genes 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 210000001236 prokaryotic cell Anatomy 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000011144 upstream manufacturing Methods 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 240000004307 Citrus medica Species 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 241000238631 Hexapoda Species 0.000 description 4
- 101001059990 Homo sapiens Mitogen-activated protein kinase kinase kinase kinase 2 Proteins 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- 241000187747 Streptomyces Species 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 230000002759 chromosomal effect Effects 0.000 description 4
- 210000000349 chromosome Anatomy 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 210000003527 eukaryotic cell Anatomy 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 238000010369 molecular cloning Methods 0.000 description 4
- 238000002888 pairwise sequence alignment Methods 0.000 description 4
- 239000013600 plasmid vector Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 235000004400 serine Nutrition 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 241001515965 unidentified phage Species 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- 241000219195 Arabidopsis thaliana Species 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 238000009007 Diagnostic Kit Methods 0.000 description 3
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 3
- 101001059982 Homo sapiens Mitogen-activated protein kinase kinase kinase kinase 5 Proteins 0.000 description 3
- 102100028199 Mitogen-activated protein kinase kinase kinase kinase 1 Human genes 0.000 description 3
- 201000004681 Psoriasis Diseases 0.000 description 3
- 102000001332 SRC Human genes 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 238000002820 assay format Methods 0.000 description 3
- 230000001042 autoregulative effect Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000013060 biological fluid Substances 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 102000048890 human MAP4K2 Human genes 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 108091006026 monomeric small GTPases Proteins 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000030938 small GTPase Human genes 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 235000002374 tyrosine Nutrition 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 208000031229 Cardiomyopathies Diseases 0.000 description 2
- 102000011068 Cdc42 Human genes 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 102100035932 Cocaine- and amphetamine-regulated transcript protein Human genes 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 101000715592 Homo sapiens Cocaine- and amphetamine-regulated transcript protein Proteins 0.000 description 2
- 101001059991 Homo sapiens Mitogen-activated protein kinase kinase kinase kinase 1 Proteins 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 101700056750 PAK1 Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 2
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 2
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- 101150065817 ROM2 gene Proteins 0.000 description 2
- 108060006706 SRC Proteins 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 102100031206 Serine/threonine-protein kinase N1 Human genes 0.000 description 2
- 108700026226 TATA Box Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000000074 antisense oligonucleotide Substances 0.000 description 2
- 238000012230 antisense oligonucleotides Methods 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 238000003287 bathing Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- VXROOKJCZCDMMS-UHFFFAOYSA-N dcht Chemical compound CC(=O)OC1C(OC(C)=O)C2(C)CC(C)CCC2C(OC(C)=O)C2CC(=O)C(C)=C1C2(C)C VXROOKJCZCDMMS-UHFFFAOYSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 230000037433 frameshift Effects 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 230000002414 glycolytic effect Effects 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 108010002838 hematopoietic progenitor kinase 1 Proteins 0.000 description 2
- 102000051937 human MAP4K5 Human genes 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 150000002614 leucines Chemical class 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000007498 myristoylation Effects 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 102000006271 p21-Activated Kinases Human genes 0.000 description 2
- 108010058266 p21-Activated Kinases Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000000865 phosphorylative effect Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000013615 primer Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000004850 protein–protein interaction Effects 0.000 description 2
- 101150090168 rab8A gene Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 206010039083 rhinitis Diseases 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 238000002864 sequence alignment Methods 0.000 description 2
- 125000003607 serino group Chemical class [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 239000006226 wash reagent Substances 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 241000203809 Actinomycetales Species 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102100034452 Alternative prion protein Human genes 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 230000020955 B cell costimulation Effects 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 108091007914 CDKs Proteins 0.000 description 1
- 101150020019 CLA4 gene Proteins 0.000 description 1
- 108010026870 Calcium-Calmodulin-Dependent Protein Kinases Proteins 0.000 description 1
- 102000019025 Calcium-Calmodulin-Dependent Protein Kinases Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 241000701489 Cauliflower mosaic virus Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 108050001278 Cdc42 Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102100034744 Cell division cycle 7-related protein kinase Human genes 0.000 description 1
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 102100021147 DNA mismatch repair protein Msh6 Human genes 0.000 description 1
- 101710099946 DNA mismatch repair protein Msh6 Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 108700010895 Drosophila ADH Proteins 0.000 description 1
- 108700022174 Drosophila Son of Sevenless Proteins 0.000 description 1
- 241000255601 Drosophila melanogaster Species 0.000 description 1
- 101100015729 Drosophila melanogaster drk gene Proteins 0.000 description 1
- 101100175356 Drosophila melanogaster gek gene Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 108010001515 Galectin 4 Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100033067 Growth factor receptor-bound protein 2 Human genes 0.000 description 1
- 102100022102 Histone-lysine N-methyltransferase 2B Human genes 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000945740 Homo sapiens Cell division cycle 7-related protein kinase Proteins 0.000 description 1
- 101000917148 Homo sapiens Fibroblast growth factor receptor 3 Proteins 0.000 description 1
- 101000871017 Homo sapiens Growth factor receptor-bound protein 2 Proteins 0.000 description 1
- 101001045848 Homo sapiens Histone-lysine N-methyltransferase 2B Proteins 0.000 description 1
- 101100182846 Homo sapiens MAP4K4 gene Proteins 0.000 description 1
- 101000950669 Homo sapiens Mitogen-activated protein kinase 9 Proteins 0.000 description 1
- 101001059984 Homo sapiens Mitogen-activated protein kinase kinase kinase kinase 4 Proteins 0.000 description 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 1
- 101000927796 Homo sapiens Rho guanine nucleotide exchange factor 7 Proteins 0.000 description 1
- 101000669917 Homo sapiens Rho-associated protein kinase 1 Proteins 0.000 description 1
- 101000652133 Homo sapiens STE20-like serine/threonine-protein kinase Proteins 0.000 description 1
- 101100204244 Homo sapiens STK24 gene Proteins 0.000 description 1
- 101000880439 Homo sapiens Serine/threonine-protein kinase 3 Proteins 0.000 description 1
- 101001129076 Homo sapiens Serine/threonine-protein kinase N1 Proteins 0.000 description 1
- 101000987317 Homo sapiens Serine/threonine-protein kinase PAK 1 Proteins 0.000 description 1
- 101000987315 Homo sapiens Serine/threonine-protein kinase PAK 3 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 101000662997 Homo sapiens TRAF2 and NCK-interacting protein kinase Proteins 0.000 description 1
- 101001022129 Homo sapiens Tyrosine-protein kinase Fyn Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 102000019145 JUN kinase activity proteins Human genes 0.000 description 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 102100037809 Mitogen-activated protein kinase 9 Human genes 0.000 description 1
- 102100025180 Mitogen-activated protein kinase kinase kinase 12 Human genes 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101000969137 Mus musculus Metallothionein-1 Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- 108010014632 NF-kappa B kinase Proteins 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000007074 Phospholipase C beta Human genes 0.000 description 1
- 108010047834 Phospholipase C beta Proteins 0.000 description 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 1
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 1
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 1
- 101150040459 RAS gene Proteins 0.000 description 1
- 101150076031 RAS1 gene Proteins 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102100039313 Rho-associated protein kinase 1 Human genes 0.000 description 1
- 108091009674 SH3 domain binding proteins Proteins 0.000 description 1
- 102000033686 SH3 domain binding proteins Human genes 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 101100149535 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) SKM1 gene Proteins 0.000 description 1
- 101000744436 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Trans-acting factor D Proteins 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 102100027911 Serine/threonine-protein kinase PAK 3 Human genes 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 230000020385 T cell costimulation Effects 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- 102100037671 TRAF2 and NCK-interacting protein kinase Human genes 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 102000028795 WW domain binding proteins Human genes 0.000 description 1
- 108091009348 WW domain binding proteins Proteins 0.000 description 1
- 210000001766 X chromosome Anatomy 0.000 description 1
- 101000752225 Xenopus laevis Low density lipoprotein receptor adapter protein 1-A Proteins 0.000 description 1
- 101100127670 Zea mays LA1 gene Proteins 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 239000013602 bacteriophage vector Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 201000011529 cardiovascular cancer Diseases 0.000 description 1
- 108020001778 catalytic domains Proteins 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 108010051348 cdc42 GTP-Binding Protein Proteins 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 241000902900 cellular organisms Species 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 230000004715 cellular signal transduction Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 101150098203 grb2 gene Proteins 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 102000047858 human MAP4K4 Human genes 0.000 description 1
- 102000044476 human PAK1 Human genes 0.000 description 1
- 102000047501 human STK3 Human genes 0.000 description 1
- 102000046188 human STK39 Human genes 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 108090001035 mitogen-activated protein kinase kinase kinase 12 Proteins 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 108010058731 nopaline synthase Proteins 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000010422 pheromone response pathway Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 150000003147 proline derivatives Chemical class 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 102000016914 ras Proteins Human genes 0.000 description 1
- 101150079601 recA gene Proteins 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 108010087686 src-Family Kinases Proteins 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000009211 stress pathway Effects 0.000 description 1
- 125000000341 threoninyl group Chemical class [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000006276 transfer reaction Methods 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 150000005691 triesters Chemical class 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 108010002164 tyrosine receptor Proteins 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 230000004862 vasculogenesis Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8178498P | 1998-04-14 | 1998-04-14 | |
| US60/081,784 | 1998-04-14 | ||
| PCT/US1999/008150 WO1999053036A2 (en) | 1998-04-14 | 1999-04-13 | Ste20-related protein kinases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2369172A1 true CA2369172A1 (en) | 1999-10-21 |
Family
ID=22166386
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002369172A Abandoned CA2369172A1 (en) | 1998-04-14 | 1999-04-13 | Ste20-related protein kinases |
Country Status (10)
| Country | Link |
|---|---|
| US (5) | US6680170B2 (enExample) |
| EP (1) | EP1073723B1 (enExample) |
| JP (1) | JP2002522009A (enExample) |
| AT (1) | ATE302269T1 (enExample) |
| AU (1) | AU3642499A (enExample) |
| CA (1) | CA2369172A1 (enExample) |
| DE (1) | DE69926742T2 (enExample) |
| DK (1) | DK1073723T3 (enExample) |
| ES (1) | ES2248997T3 (enExample) |
| WO (1) | WO1999053036A2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6861239B1 (en) | 1999-09-20 | 2005-03-01 | New York University | Genes and polynucleotides associated with ultraviolet radiation-mediated skin damage and uses thereof |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7078182B1 (en) * | 1998-04-14 | 2006-07-18 | Board Of Regents, The University Of Texas System | TAO protein kinase polypeptides and methods of use therefor |
| US6013500A (en) | 1998-05-21 | 2000-01-11 | The Trustees Of Columbia University In The City Of New York | PAK4, a novel gene encoding a serine/threonine kinase |
| EP1112368A1 (en) * | 1998-09-10 | 2001-07-04 | Smithkline Beecham Plc | Use of protein kinase kiaa0551 as pharmaceutical |
| CA2362936A1 (en) * | 1999-02-19 | 2000-08-24 | Mcmaster University | A caspase activated protein kinase |
| AU3566200A (en) * | 1999-04-01 | 2000-10-23 | Astrazeneca Uk Limited | Human signal transduction serine/threonine protein kinase |
| US6558903B1 (en) * | 1999-06-30 | 2003-05-06 | Millennium Pharmaceuticals, Inc. | Kinases and uses thereof |
| AU6181000A (en) * | 1999-07-29 | 2001-02-19 | Chugai Research Institute For Molecular Medicine, Inc. | Novel genes encoding protein kinase/protein phosphatase |
| US20030104622A1 (en) * | 1999-09-01 | 2003-06-05 | Robbins Paul D. | Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses |
| WO2001036602A2 (en) * | 1999-11-15 | 2001-05-25 | Pharmacia Italia S.P.A. | Pak5 a member of the p21-activated kinase (pak) protein family, nucleic acids and methods related to the same |
| EP1254214A2 (en) * | 2000-01-25 | 2002-11-06 | Sugen, Inc. | Human protein kinases and protein kinase-like enzymes |
| EP1385992A2 (en) * | 2000-09-20 | 2004-02-04 | Kinetek Pharmaceuticals, Inc. | Cancer associated protein kinases and their uses |
| AU2002243539A1 (en) * | 2001-01-12 | 2002-07-24 | Incyte Genomics, Inc. | Molecules for disease detection and treatment |
| US7265214B2 (en) * | 2001-10-19 | 2007-09-04 | Rigel Pharmaceuticals, Inc. | Germinal center kinase proteins, compositions and methods of use |
| JP2005518198A (ja) | 2001-12-28 | 2005-06-23 | ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク | Ｐａｋ５関連の組成物及び方法 |
| US7439329B2 (en) * | 2002-07-05 | 2008-10-21 | Sugen, Inc. | GEF-H1b: biomarkers, complexes assays and therapeutic uses thereof |
| GB0220770D0 (en) * | 2002-09-06 | 2002-10-16 | Ares Trading Sa | Proteins |
| US20050054017A1 (en) * | 2002-11-27 | 2005-03-10 | Sugen, Inc. | Phosphospecific PAK antibodies and diagnostic kits |
| AU2003296696A1 (en) * | 2002-12-23 | 2004-07-14 | Devgen Nv | Kinase sequences |
| GB2396615A (en) * | 2002-12-23 | 2004-06-30 | Devgen Nv | Kinase sequences useful for developing compounds for the prevention and/or treatment of metabolic diseases |
| US20040242461A1 (en) * | 2003-04-08 | 2004-12-02 | Schneider Michael D. | Modulators of telomere stability |
| DK1653844T3 (da) * | 2003-08-13 | 2013-03-11 | Novartis Vaccines & Diagnostic | Prionspecifikke peptidreagenser |
| US20060035242A1 (en) * | 2004-08-13 | 2006-02-16 | Michelitsch Melissa D | Prion-specific peptide reagents |
| AU2004275876B2 (en) * | 2003-09-25 | 2011-03-31 | Coley Pharmaceutical Gmbh | Nucleic acid-lipophilic conjugates |
| WO2005111234A2 (en) * | 2004-05-12 | 2005-11-24 | Sugen, Inc. | Methods of using zc1 and zc3 kinase substrate phosphorylation as biomarkers |
| NZ587255A (en) * | 2005-01-13 | 2012-03-30 | Novartis Vaccines & Diagnostic | Elisa assays using prion-specific peptide reagents |
| WO2006076683A2 (en) * | 2005-01-13 | 2006-07-20 | Novartis Vaccines And Diagnostics Inc. | Isolation and detection of pathogenic prions |
| US20090099343A1 (en) * | 2005-01-13 | 2009-04-16 | David Peretz | Isolation of pathogenic prions |
| NZ566020A (en) * | 2005-09-09 | 2012-08-31 | Novartis Ag | Prion-specific peptoid reagents |
| WO2009134942A1 (en) * | 2008-04-30 | 2009-11-05 | Novartis Ag. | Assay for pathogenic conformers |
| KR101219395B1 (ko) * | 2010-07-15 | 2013-01-11 | 전자부품연구원 | 리튬이차전지용 양극재료 및 그의 제조방법 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4343940A (en) | 1979-02-13 | 1982-08-10 | Mead Johnson & Company | Anti-tumor quinazoline compounds |
| DE3069468D1 (en) | 1979-12-19 | 1984-11-22 | Nat Res Dev | Quinazoline derivatives, processes for their preparation, compositions containing them and their use as anti-cancer agents |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4945050A (en) | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
| DE3611194A1 (de) | 1986-04-04 | 1987-10-08 | Bayer Ag | Cancerostatisches mittel |
| US5217999A (en) | 1987-12-24 | 1993-06-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Styryl compounds which inhibit EGF receptor protein tyrosine kinase |
| DE3920029C2 (de) | 1988-06-30 | 1999-05-20 | Clariant Finance Bvi Ltd | Farbstoffe zum Färben von Kunststoffen |
| ATE114661T1 (de) | 1990-04-02 | 1994-12-15 | Pfizer | Benzylphosphonsäure-tyrosinkinaseinhibitoren. |
| US5302606A (en) | 1990-04-16 | 1994-04-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase |
| AU658646B2 (en) | 1991-05-10 | 1995-04-27 | Rhone-Poulenc Rorer International (Holdings) Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| JPH06503095A (ja) | 1991-05-29 | 1994-04-07 | ファイザー・インコーポレーテッド | 三環式ポリヒドロキシ系のチロシンキナーゼ阻害薬 |
| NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
| US5298422A (en) | 1991-11-06 | 1994-03-29 | Baylor College Of Medicine | Myogenic vector systems |
| GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
| GB9205320D0 (en) | 1992-03-11 | 1992-04-22 | Ici Plc | Anti-tumour compounds |
| EP0654024A1 (en) | 1992-08-06 | 1995-05-24 | Warner-Lambert Company | 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties |
| US5330992A (en) | 1992-10-23 | 1994-07-19 | Sterling Winthrop Inc. | 1-cyclopropyl-4-pyridyl-quinolinones |
| US5366889A (en) * | 1992-11-30 | 1994-11-22 | The General Hospital Corporation | DNA encoding a protein-coupled receptor kinase |
| GB9226855D0 (en) | 1992-12-23 | 1993-02-17 | Erba Carlo Spa | Vinylene-azaindole derivatives and process for their preparation |
| GB9501567D0 (en) | 1995-01-26 | 1995-03-15 | Pharmacia Spa | Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors |
| US5830699A (en) * | 1996-05-07 | 1998-11-03 | The General Hospital Corporation | SOK-1 and methods of use |
| AU4448597A (en) | 1996-10-04 | 1998-05-05 | Connaught Laboratories Limited | Treatment of cancer using a recombinant poxvirus containing nucleic acid sequence encoding a cytokine |
| AU8296698A (en) * | 1997-07-08 | 1999-02-08 | Cadus Pharmaceutical Corporation | (kds) protein kinase molecules and uses related thereto |
| AU8778698A (en) * | 1997-08-11 | 1999-03-01 | Ontogeny, Inc. | Serine/threonine kinase, and uses related thereto |
| GB9719920D0 (en) * | 1997-09-19 | 1997-11-19 | Zeneca Ltd | Human Ste20-Like Stress Activated Serine/Threonine Kinase |
| GB9726851D0 (en) * | 1997-12-19 | 1998-02-18 | Zeneca Ltd | Human signal transduction serine/threonine kinase |
| US6013500A (en) * | 1998-05-21 | 2000-01-11 | The Trustees Of Columbia University In The City Of New York | PAK4, a novel gene encoding a serine/threonine kinase |
-
1999
- 1999-04-13 DE DE69926742T patent/DE69926742T2/de not_active Expired - Fee Related
- 1999-04-13 WO PCT/US1999/008150 patent/WO1999053036A2/en not_active Ceased
- 1999-04-13 DK DK99918539T patent/DK1073723T3/da active
- 1999-04-13 US US09/291,417 patent/US6680170B2/en not_active Expired - Fee Related
- 1999-04-13 JP JP2000543584A patent/JP2002522009A/ja not_active Withdrawn
- 1999-04-13 AU AU36424/99A patent/AU3642499A/en not_active Abandoned
- 1999-04-13 ES ES99918539T patent/ES2248997T3/es not_active Expired - Lifetime
- 1999-04-13 AT AT99918539T patent/ATE302269T1/de not_active IP Right Cessation
- 1999-04-13 CA CA002369172A patent/CA2369172A1/en not_active Abandoned
- 1999-04-13 EP EP99918539A patent/EP1073723B1/en not_active Expired - Lifetime
-
2000
- 2000-10-16 US US09/688,188 patent/US6656716B1/en not_active Expired - Fee Related
-
2003
- 2003-12-02 US US10/725,329 patent/US20040224323A1/en not_active Abandoned
- 2003-12-02 US US10/725,121 patent/US20050142625A1/en not_active Abandoned
- 2003-12-02 US US10/725,330 patent/US20070072261A1/en not_active Abandoned
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6861239B1 (en) | 1999-09-20 | 2005-03-01 | New York University | Genes and polynucleotides associated with ultraviolet radiation-mediated skin damage and uses thereof |
| US6953664B2 (en) | 1999-09-20 | 2005-10-11 | New York University | Genes and polynucleotides associated with ultraviolet radiation-mediated skin damage and uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| ATE302269T1 (de) | 2005-09-15 |
| US6680170B2 (en) | 2004-01-20 |
| US20050142625A1 (en) | 2005-06-30 |
| WO1999053036A2 (en) | 1999-10-21 |
| ES2248997T3 (es) | 2006-03-16 |
| DK1073723T3 (da) | 2006-01-02 |
| JP2002522009A (ja) | 2002-07-23 |
| EP1073723A2 (en) | 2001-02-07 |
| WO1999053036A3 (en) | 2000-05-11 |
| AU3642499A (en) | 1999-11-01 |
| US20030050230A1 (en) | 2003-03-13 |
| DE69926742T2 (de) | 2006-06-14 |
| EP1073723B1 (en) | 2005-08-17 |
| US20040224323A1 (en) | 2004-11-11 |
| DE69926742D1 (de) | 2005-09-22 |
| US20070072261A1 (en) | 2007-03-29 |
| US6656716B1 (en) | 2003-12-02 |
| WO1999053036A9 (en) | 2000-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6680170B2 (en) | Polynucleotides encoding STE20-related protein kinases and methods of use | |
| US20050125852A1 (en) | Novel kinases | |
| US20040197792A1 (en) | Novel Kinases | |
| WO2000073469A2 (en) | Protein kinases | |
| WO1999037788A9 (en) | Diagnosis and treatment of aur1 and/or aur2 related disorders | |
| US20060140954A1 (en) | Novel human protein kinases and protein kinase-like enzymes | |
| EP1088079A2 (en) | Nek-related and bub1-related protein kinases | |
| US6388063B1 (en) | Diagnosis and treatment of SAD related disorders | |
| US6495353B1 (en) | Human orthologues of wart | |
| AU2001251510A1 (en) | Human protein kinases and protein kinase-like enzymes | |
| US6844177B2 (en) | Diagnosis and treatment of PTP04 related disorders | |
| EP1595946A2 (en) | STE20-related protein kinases | |
| US20030211989A1 (en) | Novel human protein kinases and protein kinase-like enzymes | |
| US6342593B1 (en) | Diagnosis and treatment of ALP related disorders | |
| US20030224378A1 (en) | Novel human protein kinases and protein kinase-like enzymes | |
| EP1533378A2 (en) | Tyrosine kinase substrate protein Tks7 | |
| CA2365623A1 (en) | Tyrosine kinase substrate (tks) proteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |